Long-term Alterations of Host-microbiome Interactions and Cardiovascular and Respiratory Diseases Progression After Pneumonia
Long-term Alterations of Host-microbiome Interactions and Cardiovascular and Respiratory Diseases Progression After Pneumonia - the HOMI-LUNG Project - Hospital-Acquired-Pneumonia
Nantes University Hospital
300 participants
Jan 2, 2025
INTERVENTIONAL
Conditions
Summary
The HOMI-LUNG - HAP study is part of the HOMI-LUNG project, funded by the Horizon Europe program. The "HOMI-LUNG" project is an international, interdisciplinary project that aims to better understand the causal links between respiratory tract infections (i.e. pneumonia) and the progression of cardiovascular disease. More specifically, the project aims to quantify the burden of cardiovascular disease after pneumonia and assess patients\' acceptability of long-term health alterations, as well as to define pneumonia endotypes with distinct pathobiological mechanisms associated with exacerbation of cardiovascular disease.
Eligibility
Inclusion Criteria29
- Group A (patients with acute cardiac disease)
- Male or female
- Age ≥ 40years old
- Hospitalized for acute coronary syndrome for less than 7 days.
- Informed consent from the patient
- Person insured under a health insurance scheme
- Group B (patients with chronic cardiovascular disease)
- Male or female,
- Age ≥ 40 years old
- Undergoing coronary artery by-pass surgery
- Hospitalized in intensive care unit for \> 12 hours
- Informed consent from the patient
- Person insured under a health insurance scheme
- Group C (patients at risk of CVRD without chronic cardiovascular disease)
- Male or female,
- Age ≥ 40 years old
- Familial high levels of cholesterol or triglycerides
- With no personal history of CVRD, with a recent negative cardiac exercise test (last test inferior to 12 months)
- Follow-up for lipid abnormalities at high risk of CVRD events
- Informed consent from the patient
- Person insured under a health insurance scheme
- Group D (patients with HAP)
- Male or female
- Age ≥ 40years old
- With one or more risk factors for CVD among:
- smoking, abnormal lipidic levels, high blood pressure, obesity, diabetes mellitus, chronic kidney disease
- Cured from mechanically ventilated HAP during the current hospitalization
- Informed consent from the patient or relatives
- Person insured under a health insurance scheme
Exclusion Criteria8
- o Groups A, B, C and D
- Age \>80 years old
- Immunosuppression pre-existing to the index hospitalisation, defined as lymphopenia \< 500 elements/mm3, haematologic cancer, aplasia, chemotherapy/radiotherapy for cancer within 3 months prior to the inclusion, or anti-graft rejection drug.
- Pregnant women, breastfeeding women.
- Adults under guardianship or trusteeship.
- Low probability of survival at day 28.
- o Groups A, B, C
- Community-acquired pneumonia or Hospital-acquired pneumonia within the last year.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Four blood samples will be taken outside standard care for groups A, B, C and D: at inclusion, M6, M18 and M30 (only at inclusion for group C).
An oropharyngeal swab will be taken to analyze patients\' upper airway microbiome at inclusion, M6, M18 and M30.
A calcium score will be taken at 30 months, to assess individual cardiovascular risk.
Performed at inclusion, M6, M18 and M30
Cardiopulmonary exercise test, spirometry, plethysmography, pulmonary absorption of carbon monoxide in a single inspiration, and 6-minute walk test: These tests will be performed consecutively for 2 hours at inclusion (6-minute walk test only), at M6 and at M30. These tests will be performed to assess respiratory and cardiac function.
Locations(5)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06602934